Moleculin Biotech: Annamycin in Combination With Cytarabine (Annarac) Achieves Crc Rate of 62% (54% Cr) in 1(St) and 2(Nd) Line Aml Subjects (N=13)
Moleculin Biotech:安那黴素與阿糖胞苷(Annarac)聯合使用可使1(St)和2(Nd)系急性髓細胞白血病受試者(N=13)的結直腸癌率達到 62%(54% Cr)
Moleculin Biotech: Annamycin in Combination With Cytarabine (Annarac) Achieves Crc Rate of 62% (54% Cr) in 1(St) and 2(Nd) Line Aml Subjects (N=13)
Moleculin Biotech:安那黴素與阿糖胞苷(Annarac)聯合使用可使1(St)和2(Nd)系急性髓細胞白血病受試者(N=13)的結直腸癌率達到 62%(54% Cr)
使用瀏覽器的分享功能,分享給你的好友吧